1.Lee MS, Flammer AJ, Lerman LO, Lerman A. Personalized
medicine in cardiovascular diseases. Korean Circ J.
2012;42(9):583-91. doi: 10.4070/kcj.2012.42.9.583 pmid:
23091501
2. Vodkin I, Kuo A. Extended Criteria Donors in Liver
Transplantation. Clin Liver Dis. 2017;21(2):289-301. doi:
10.1016/j.cld.2016.12.004 pmid: 28364814
3. Attia M, Silva MA, Mirza DF. The marginal liver donor--an
update. Transpl Int. 2008;21(8):713-24. doi: 10.1111/j.1432-
2277.2008.00696.x pmid: 18492121
4. Busuttil RW, Tanaka K. The utility of marginal donors in liver
transplantation. Liver Transpl. 2003;9(7):651-63. doi:
10.1053/jlts.2003.50105 pmid: 12827549
5. Spitzer AL, Lao OB, Dick AA, Bakthavatsalam R, Halldorson
JB, Yeh MM, et al. The biopsied donor liver: incorporating
macrosteatosis into high-risk donor assessment. Liver Transpl.
2010;16(7):874-84. doi: 10.1002/lt.22085 pmid: 20583086
6. Seket B, Abdelaal A, Gelas T, Pittau G, Dumortier J, Vanhems
P, et al. Back-table reconstruction of the donor replaced right
hepatic artery prior to liver transplantation: what is the real
impact on arterial complications? Hepatogastroenterology.
2009;56(91-92):756-62. pmid: 19621697
7. Mojtabaee M, Shamsaeefar A, Gholami S, Mohsenzadeh M,
Sadegh Beigee F. Impact of a Full-Time Donor Management
Protocol on Donors' Liver Biopsy Findings: Progress to Date.
Exp Clin Transplant. 2017;15(Suppl 1):269-72. doi:
10.6002/ect.mesot2016.P135 pmid: 28260484
